Phathom Pharmaceuticals, Inc.
https://www.phathompharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Phathom Pharmaceuticals, Inc.
Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
Orthopedics Corner: Catalyst Looks To Clinical Data To Distinguish Its Shoulder Arthroplasty Technology
Orthopedics Corner is a new series highlighting new developments in spine and orthopedics technology you may have missed. Catalyst OrthoScience CEO Carl O’Connell, along with surgeon and researcher Matthew Budge, talked to Medtech Insight about Catalyst’s innovation in shoulder arthroplasty.
Finance Watch: No Big Post-ASCO Follow-On Frenzy, But Biotech Had A Good Week
Public Company Edition: Follow-on offerings did not surge after ASCO, but Day One and Cogent raised $150m-plus. Also, IQVIA and Ionis sold $1.25bn and $500m in notes, while Krystal and Lexicon grossed $160m and $125m from post-approval offerings.
Podcast Special: J&J's Andrie Leday Addresses ASC Market With Customized Approach
In this special podcast from Medtech Insight, editor Reed Miller talked to Andrie Leday, the US vice president for ambulatory surgery centers (ASCs) at Johnson & Johnson/DePuy Synthes. Leday's group is dedicated to creating a new "ecosystem" around DePuy Synthes' broad range of orthopedic implants and tools to meet the demand of an aging population.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice